David J. Drachman served as the CEO of AtriCure, Inc., a medical device company, from its founding in 2000 until September 2012. He played a significant role in shaping the company's growth in the medical device industry. In 2010, he...

David J. Drachman served as the CEO of AtriCure, Inc., a medical device company, from its founding in 2000 until September 2012. He played a significant role in shaping the company's growth in the medical device industry. In 2010, he earned a total compensation of $620,468, which included a performance-based bonus for achieving operational goals. Drachman made some notable insider trades; for example, between September 2019 and January 2021, the value of his holdings fluctuated significantly, reaching a peak of $19.05 million in July 2021 before settling at about $10.22 million by January 2023. Interestingly, after resigning, he continued a unique agreement that allowed him to receive benefits until 2013. Drachman's tenure as CEO was marked by a commitment to aligning executive pay with the company's performance, showing a structured approach to leadership in a competitive market.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other AtriCure CEOs

A

David J. Drachman

Ex-CEO of AtriCure

Sector of Economy

Healthcare

CEO of AtriCure for

10 years 8 months (Jan 2002 - Sep 2012)

Previous Experience

Unknown

Rivals

Competitors/colleagues of David J. Drachman

Holdings

See how much did David J. Drachman make over time.

David J. Drachman's stock holdings in AtriCure saw significant fluctuations during 2019 to 2021. His holdings started at about $5.88 million in September 2019, gradually increasing each month, hitting $19.05 million by July 2021. However, the value then began a...

David J. Drachman's stock holdings in AtriCure saw significant fluctuations during 2019 to 2021. His holdings started at about $5.88 million in September 2019, gradually increasing each month, hitting $19.05 million by July 2021. However, the value then began a slow decline, leveling out at around $10.22 million in January 2023. These moves reflect an active trading strategy that capitalized on market shifts. Such fluctuations provide insight into the confidence and expectations a CEO may have regarding company performance and market conditions.

Loading...

Total Stock Sold

$3.81M

ATRC

$3.81M

481,154 ATRC shares

What if they kept their stock?

If David J. Drachman didn't sell their stock, today they would have:
Extra ATRC481,154 shares worth $20.68M.
This is 443.37% and $16.87M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of David J. Drachman.

ATRC

$140.80K

ATRC at $7.04/share

Sep 12, 2012

Sale

ATRC

$1.58M

ATRC at $6.63/share

Sep 5, 2012

Sale

ATRC

$553.35K

ATRC at $7.23/share

Aug 14, 2012

Sale

ATRC

$103.70K

ATRC at $8.13/share

May 23, 2012

Sale

ATRC

$321.90K

ATRC at $8.22/share

May 18, 2012

Sale

ATRC

$209.09K

ATRC at $9.07/share

May 8, 2012

Sale

ATRC

36,000 shares

ATRC

Feb 15, 2012

Received

ATRC

$420.00K

ATRC at $14.00/share

Jun 13, 2011

Sale

ATRC

$434.34K

ATRC at $10.68/share

Feb 23, 2011

Sale

ATRC

120,000 shares

ATRC

Feb 9, 2011

Received

Compensation History

See how much did David J. Drachman make over time.

In 2012, David J. Drachman's compensation totaled $1,261,866, making it a notable year in his tenure. His salary was $337,500, and although he waived his bonus rights for 2012 due to his resignation, he received substantial other compensation worth $638,870, which included severance payments as per his employment agreement. Earlier in 2010, his total pay was $620,468, with a performance bonus for meeting financial goals, highlighting a structured approach to compensation that ties executive pay to company performance. This pay-for-performance philosophy was a key part of his leadership at AtriCure.

Year

2012

Total Compensation

$1.33M

Salary

$337.50K

Board Justification

The compensation philosophy is rooted in a pay-for-performance approach, linking executive compensation to company performance and individual contributions.

Bonus

$0.00

Board Justification

Mr. Drachman waived all rights to receive payment of an annual incentive bonus for 2012 due to his resignation.

Other

$638.87K

Board Justification

This includes severance payments and other benefits as per his employment agreement upon resignation.

Restricted Stock

$357.12K(357.12K RSU)

Board Justification

The stock awards that vested in 2012 were part of the long-term incentive plan and were granted prior to his resignation.

Performance Metrics

The performance metrics for determining compensation included company-wide financial and operational goals.

Other AtriCure CEOs

Here are other CEOs of AtriCure

Michael H. Carrel

CEO of AtriCure

November 2012 - Present